Promacta and Valsartan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Promacta (eltrombopag olamine) and Valsartan (valsartan). Common drug interactions include death among females and haemoptysis among males.

The phase IV clinical study analyzes what interactions people have when they take Promacta and Valsartan. It is created by eHealthMe based on reports of 20 people who take the same drugs from the FDA, and is updated regularly.

What is Promacta?

Promacta has active ingredients of eltrombopag olamine. It is often used in idiopathic thrombocytopenic purpura (itp). eHealthMe is studying from 17,758 Promacta users. Check the latest studies of Promacta.

What is Valsartan?

Valsartan has active ingredients of valsartan. It is often used in high blood pressure. eHealthMe is studying from 63,805 Valsartan users. Check the latest studies of Valsartan.

On Jul, 15, 2026

20 people who take Promacta and Valsartan together, and have interactions are studied.

Promacta and Valsartan drug interactions.

What are the common drug interactions of Promacta and Valsartan, by gender? *:

female:

Death
Platelet count increased
Infection
Platelet count decreased
Acute respiratory failure
Anaemia (lack of blood)
Antiphospholipid syndrome (disorder that manifests clinically as recurrent venous or arterial thrombosis and/or fetal loss)
Apnoea (suspension of external breathing)
Arthritis (form of joint disorder that involves inflammation of one or more joints)
Autoimmune disorder (a condition in which the immune system attacks the body's normal substances and tissue)

male:

Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Activated partial thromboplastin time prolonged
Eosinophil count decreased
Faeces discoloured
Fatigue (feeling of tiredness)
Gastrointestinal motility disorder (abnormal intestinal contractions)
General physical health deterioration (weak health status)
Glomerular filtration rate decreased
Haemangioma (noncancerous, abnormally dense collections of dilated small blood vessels that may occur in the skin or internal organs)
Hot flush (sudden feelings of heat)

What are the common drug interactions of Promacta and Valsartan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Acute myocardial infarction (acute heart attack)
Device occlusion
Death

50-59:

n/a

60+:

Blood pressure diastolic decreased
Blood pressure systolic increased
Death
Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
Gangrene (body tissue dies)
General physical health deterioration (weak health status)
Haemoglobin decreased
Infection
Platelet count decreased
Sepsis (a severe blood infection that can lead to organ failure and death)

What are the existing conditions these people have? *

Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 10.00%
Infection: 2 people, 10.00%
Thrombocytopenia (decrease of platelets in blood): 1 person, 5.00%
Pain: 1 person, 5.00%
Joint Pain: 1 person, 5.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 5.00%
Fibromyalgia (a long-term condition which causes pain all over the body): 1 person, 5.00%
Enlarged Prostate: 1 person, 5.00%
Diabetes: 1 person, 5.00%
Cardiac Disorder: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Promacta and Valsartan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously